125
Views
1
CrossRef citations to date
0
Altmetric
Review

Utilizing clinical pharmacology in the drug repurposing arena: a look into COVID-19

, , , , , & show all
Pages 1225-1231 | Received 04 May 2022, Accepted 30 Sep 2022, Published online: 08 Oct 2022

References

  • Velavan TP, Meyer CG. The COVID‐19 epidemic. Trop Med Int Health. 2020;25(3):278.
  • Park JW, Lagniton PNP, Liu Y, et al. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci. 2021;17(6):1446–1460.
  • Dodds M, Xiong Y, Mouksassi S, et al. Model-informed drug repurposing: a pharmacometric approach to novel pathogen preparedness, response and retrospection. Br J Clin Pharmacol. 2021;87(9):3388–3397.
  • Lapeyre-Mestre M, Montastruc F. Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs. Therapie. 2019;74(2):209–214.
  • Gulmez SE, Aydin V, Akici A. Footprints of clinical pharmacology in Turkey: Past, Present, and Future. Clin Ther. 2020;42(2):351–362.
  • Waldman SA, Terzic A. Clinical pharmacology at the core of translational science. Expert Rev Clin Pharmacol. 2011;4(3):303.
  • Van Der Graaf PH, Giacomini KM. COVID-19: a defining moment for clinical pharmacology? Clin Pharmacol Ther. 2020;108(1):11–15.
  • Osborne V, Davies M, Lane S, et al. Lopinavir-Ritonavir in the treatment of COVID-19: a dynamic systematic benefit-risk assessment. Drug Saf. 2020;43(8):809–821.
  • Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. Internet]. 2009 cited 2022 Jun 29;22(2):119. Available from: https://pubmed.ncbi.nlm.nih.gov/19330170/
  • Antoszczak M, Markowska A, Markowska J, et al. Old wine in new bottles: drug repurposing in oncology. Eur J Pharmacol. 2020;866:172784.
  • Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov Internet]. 2019 cited 2022 Jun 29;18(1):41–58. Available from: https://pubmed.ncbi.nlm.nih.gov/30310233/
  • Xue H, Li J, Xie H, et al. Review of drug repositioning approaches and resources. Int J Biol Sci. 2018;14(10):1232.
  • Gil C, Martinez A. Is drug repurposing really the future of drug discovery or is new innovation truly the way forward? Expert Opin Drug Discov. 2021;16(8):829–831.
  • Muratov EN, Amaro R, Andrade CH, et al. A critical overview of computational approaches employed for COVID-19 drug discovery. Chem Soc Rev Internet]. 2021 cited 2022 Jun 30;50(16):9121–9151. Available from: https://pubs.rsc.org/en/content/articlehtml/2021/cs/d0cs01065k
  • Talevi A, Bellera CL. Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. Expert Opinion on Drug Discovery. 2019;15(4):397–401.
  • Frouws MA, Bastiaannet E, Langley RE, et al. Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study. Br J Cancer. 2017;116(3):405.
  • Huang XZ, Chen Y, Wu J, et al. Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: a dose-response meta-analysis. Oncotarget. 2017;8(3):4781.
  • Langley RE, Burdett S, Tierney JF, et al. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer. 2011;105(8):1107–1113.
  • WHO. Repurposing of medicines in oncology-the underrated champion of sustainable innovation. Policy brief. Copenhagen: WHO Regional Office for Europe. 2021.
  • Medicines European Agency. Repurposing of authorised medicines: pilot to support not-for-profit organisations and academia | European Medicines Agency [Internet]. cited 2022 Apr 5]. Available from 2022 Apr 5: https://www.ema.europa.eu/en/news/repurposing-authorised-medicines-pilot-support-not-profit-organisations-academia
  • Hanisch M, Rake B. Repurposing without purpose? Early innovation responses to the COVID-19 crisis: evidence from clinical trials. R&D Management. 2021;51(4):393–409.
  • Zhou Y, Wang F, Tang J, et al. Artificial intelligence in COVID-19 drug repurposing. Lancet Digital Health. 2020;2(12):e667–e676.
  • Akbarzadeh-Khiavi M, Torabi M, Rahbarnia L, et al. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection. Infection. 2022;50(2):295–308.
  • Noreen S, Maqbool I, Madni A. Dexamethasone: therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol. 2021;894:173854.
  • Pelaia C, Calabrese C, Garofalo E, et al. Therapeutic role of tocilizumab in SARS-CoV-2-Induced cytokine storm: rationale and current evidence. Int J Mol Sci. 2021;22(6):3059.
  • Fricke-Galindo I, Falfán-Valencia R, Sharma P. Pharmacogenetics approach for the improvement of COVID-19 treatment. Viruses. 2021;14(1):13.
  • Rafaniello C, Ferrajolo C, Sullo MG, et al. Cardiac events potentially associated to remdesivir: an analysis from the European spontaneous adverse event reporting system. Pharmaceuticals. 2021;15(1):14.
  • Chakraborty C, Sharma AR, Bhattacharya M, et al. The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies. Front Pharmacol. 2021;12:704205.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.